CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

by Lieberman, Linda A., Zeng, Wanyong, Singh, Carol, Wang, Wenting, Otipoby, Kevin L., Loh, Christine, Plavina, Tatiana, Gorelik, Leonid, Ransohoff, Richard M., Cahir-McFarland, Ellen
Published 2016